Clinical Trials Logo

Refractory B-Cell Lymphoma clinical trials

View clinical trials related to Refractory B-Cell Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03824964 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: February 1, 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19/CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.

NCT ID: NCT03824951 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: February 1, 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 iCAR NK cells in patients with relapsed refractory B cell lymphoma.

NCT ID: NCT03692767 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: March 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.

NCT ID: NCT03690310 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: March 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 CAR NK cells in patients with relapsed refractory B cell lymphoma.